Loading
companiesCompany
ALX Oncology
ALX Oncology is a Californian biotechnology company developing evorpacept, a CD47-blocking fusion protein designed to remove the 'do not eat me' signal so that antibodies such as trastuzumab can recruit macrophages against HER2-positive gastric cancer.
Also called: ALX Oncology Holdings
Overview
ALX Oncology, based in South San Francisco, develops evorpacept (ALX148), an engineered SIRP-alpha fusion protein that blocks CD47 without the red-cell toxicity of earlier CD47 antibodies, so it can be combined with tumour-targeting antibodies to enhance macrophage attack. Its lead trial ASPEN-06 tests evorpacept with trastuzumab, ramucirumab and paclitaxel in previously treated HER2-positive gastric cancer, and the company is studying the drug in other antibody combinations. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
South San Francisco, CA, US
Scorecard
All companies#339of 1244 companies, score 11
- phase 3 +3
- modalities +2
- registry trials +6
0 approved, 1 in phase 3, 0 earlier, 0 targets, 10 registry studies. Formula on the scorecards page.
Type
Stage
Public
Website
Phase 3immune checkpoint modulator
Evorpacept is an experimental immune checkpoint modulator from ALX Oncology in phase 3 trials for gastric & gastro-oesophageal junction cancer, HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, with its target not yet stated publicly.
Similar pages
- TechnologyCD47 and SIRP-alpha blockade
Shares A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06), Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03), Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04), Evorpacept.
- TreatmentSpevatamig
cancers
fronts
targets
drugs
Phase 3immune checkpoint modulator
trials
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerEvorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)PRE-ISPY Phase I/II Oncology Platform Program